139 related articles for article (PubMed ID: 12563278)
1. In situ assembly of enzyme inhibitors using extended tethering.
Erlanson DA; Lam JW; Wiesmann C; Luong TN; Simmons RL; DeLano WL; Choong IC; Burdett MT; Flanagan WM; Lee D; Gordon EM; O'Brien T
Nat Biotechnol; 2003 Mar; 21(3):308-14. PubMed ID: 12563278
[TBL] [Abstract][Full Text] [Related]
2. Fragment-based discovery of nonpeptidic BACE-1 inhibitors using tethering.
Yang W; Fucini RV; Fahr BT; Randal M; Lind KE; Lam MB; Lu W; Lu Y; Cary DR; Romanowski MJ; Colussi D; Pietrak B; Allison TJ; Munshi SK; Penny DM; Pham P; Sun J; Thomas AE; Wilkinson JM; Jacobs JW; McDowell RS; Ballinger MD
Biochemistry; 2009 Jun; 48(21):4488-96. PubMed ID: 19284778
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a new phosphotyrosine mimetic for PTP1B using breakaway tethering.
Erlanson DA; McDowell RS; He MM; Randal M; Simmons RL; Kung J; Waight A; Hansen SK
J Am Chem Soc; 2003 May; 125(19):5602-3. PubMed ID: 12733877
[TBL] [Abstract][Full Text] [Related]
4. Using peptidic inhibitors to systematically probe the S1' site of caspase-3 and caspase-7.
Goode DR; Sharma AK; Hergenrother PJ
Org Lett; 2005 Aug; 7(16):3529-32. PubMed ID: 16048334
[TBL] [Abstract][Full Text] [Related]
5. A novel method for evaluation and screening of caspase inhibitory peptides by the amino acid positional fitness score.
Yoshimori A; Takasawa R; Tanuma S
BMC Pharmacol; 2004 May; 4():7. PubMed ID: 15154972
[TBL] [Abstract][Full Text] [Related]
6. Discovery of an Aurora kinase inhibitor through site-specific dynamic combinatorial chemistry.
Cancilla MT; He MM; Viswanathan N; Simmons RL; Taylor M; Fung AD; Cao K; Erlanson DA
Bioorg Med Chem Lett; 2008 Jul; 18(14):3978-81. PubMed ID: 18579375
[TBL] [Abstract][Full Text] [Related]
7. Reducing the peptidyl features of caspase-3 inhibitors: a structural analysis.
Becker JW; Rotonda J; Soisson SM; Aspiotis R; Bayly C; Francoeur S; Gallant M; Garcia-Calvo M; Giroux A; Grimm E; Han Y; McKay D; Nicholson DW; Peterson E; Renaud J; Roy S; Thornberry N; Zamboni R
J Med Chem; 2004 May; 47(10):2466-74. PubMed ID: 15115390
[TBL] [Abstract][Full Text] [Related]
8. Structural analysis of caspase-1 inhibitors derived from Tethering.
O'Brien T; Fahr BT; Sopko MM; Lam JW; Waal ND; Raimundo BC; Purkey HE; Pham P; Romanowski MJ
Acta Crystallogr Sect F Struct Biol Cryst Commun; 2005 May; 61(Pt 5):451-8. PubMed ID: 16511067
[TBL] [Abstract][Full Text] [Related]
9. Conformationally restricted hydantoin-based peptidomimetics as inhibitors of caspase-3 with basic groups allowed at the S3 enzyme subsite.
Vázquez J; García-Jareño A; Mondragón L; Rubio-Martinez J; Pérez-Payá E; Albericio F
ChemMedChem; 2008 Jun; 3(6):979-85. PubMed ID: 18393268
[TBL] [Abstract][Full Text] [Related]
10. Slow-binding human serine racemase inhibitors from high-throughput screening of combinatorial libraries.
Dixon SM; Li P; Liu R; Wolosker H; Lam KS; Kurth MJ; Toney MD
J Med Chem; 2006 Apr; 49(8):2388-97. PubMed ID: 16610782
[TBL] [Abstract][Full Text] [Related]
11. Reversible inhibition of caspase-3 activity by iron(III): potential role in physiological control of apoptosis.
Sliskovic I; Mutus B
FEBS Lett; 2006 Apr; 580(9):2233-7. PubMed ID: 16579993
[TBL] [Abstract][Full Text] [Related]
12. Dynamic combinatorial self-assembly of cyclophilin hCyp-18 ligands through oxorhenium coordination.
Clavaud C; Le Gal J; Thai R; Moutiez M; Dugave C
Chembiochem; 2008 Jul; 9(11):1823-9. PubMed ID: 18604836
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and structure-activity relationship of 4-substituted 2-(2-acetyloxyethyl)-8-(morpholine-4-sulfonyl)pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors.
Kravchenko DV; Kuzovkova YA; Kysil VM; Tkachenko SE; Maliarchouk S; Okun IM; Balakin KV; Ivachtchenko AV
J Med Chem; 2005 Jun; 48(11):3680-3. PubMed ID: 15916416
[TBL] [Abstract][Full Text] [Related]
14. Conformational restrictions in the active site of unliganded human caspase-3.
Ni CZ; Li C; Wu JC; Spada AP; Ely KR
J Mol Recognit; 2003; 16(3):121-4. PubMed ID: 12833566
[TBL] [Abstract][Full Text] [Related]
15. Identification of early intermediates of caspase activation using selective inhibitors and activity-based probes.
Berger AB; Witte MD; Denault JB; Sadaghiani AM; Sexton KM; Salvesen GS; Bogyo M
Mol Cell; 2006 Aug; 23(4):509-21. PubMed ID: 16916639
[TBL] [Abstract][Full Text] [Related]
16. Lipophilic versus hydrogen-bonding effect in P3 on potency and selectivity of valine aspartyl ketones as caspase 3 inhibitors.
Mellon C; Aspiotis R; Black CW; Bayly CI; Grimm EL; Giroux A; Han Y; Isabel E; McKay DJ; Nicholson DW; Rasper DM; Roy S; Tam J; Thornberry NA; Vaillancourt JP; Xanthoudakis S; Zamboni R
Bioorg Med Chem Lett; 2005 Sep; 15(17):3886-90. PubMed ID: 16023344
[TBL] [Abstract][Full Text] [Related]
17. Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation.
Kutuk O; Pedrech A; Harrison P; Basaga H
Apoptosis; 2005 May; 10(3):597-609. PubMed ID: 15909121
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of isoquinoline-1,3,4-trione derivatives as potent caspase-3 inhibitors.
Chen YH; Zhang YH; Zhang HJ; Liu DZ; Gu M; Li JY; Wu F; Zhu XZ; Li J; Nan FJ
J Med Chem; 2006 Mar; 49(5):1613-23. PubMed ID: 16509578
[TBL] [Abstract][Full Text] [Related]
19. "Click" synthesis of small-molecule inhibitors targeting caspases.
Ng SL; Yang PY; Chen KY; Srinivasan R; Yao SQ
Org Biomol Chem; 2008 Mar; 6(5):844-7. PubMed ID: 18292873
[TBL] [Abstract][Full Text] [Related]
20. Solid phase synthesis of selective caspase-3 peptide inhibitors.
Grimm EL; Roy B; Aspiotis R; Bayly CI; Nicholson DW; Rasper DM; Renaud J; Roy S; Tam J; Tawa P; Vaillancourt JP; Xanthoudakis S; Zamboni RJ
Bioorg Med Chem; 2004 Mar; 12(5):845-51. PubMed ID: 14980595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
